Combination NTI drugs offer critical treatment for complex conditions, but generic versions are nearly nonexistent due to strict bioequivalence challenges. Patients face higher risks of failure and toxicity when substitutions occur.
March 12 2026
Switching patients to generic NTI drugs requires careful communication and monitoring. Learn how to explain therapeutic equivalence, address patient fears, follow state laws, and ensure safety with proven strategies backed by the FDA and clinical evidence.
January 31 2026